891
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Antibody based immunotherapy for multiple myeloma: it’s about time

&
Pages 269-275 | Received 31 Aug 2015, Accepted 04 Sep 2015, Published online: 16 Dec 2015
 

Abstract

Monoclonal antibodies have made an indelible impact on cancer practice. Historically multiple myeloma (MM) has lagged behind in benefitting from this treatment modality. Recent years have seen a tremendous increase in the number of therapeutic antibodies being developed for treatment of MM. Unconjugated anti-CD 38 antibody Daratumumab and the anti-SLAMF7 antibody elotuzumab are in advanced stages of development and are expected to have a major impact in the management of MM. The immunotoxin Indatuximab Ravtansine is in early stages of development and the results appear encouraging. The role of monoclonal antibodies in myeloma will continue to evolve and, like other lymphoid malignancies, they are likely to have the greatest impact when combined with other anti-myeloma agents.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.